Thiruvengadam Muniraj

Dr. Thiruvengadam Muniraj


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Disease-a-Month
Verified
Journal Article
Closed access
RLRobert Lam
Robert Lam
AZAlan Zakko
Alan Zakko
JPJessica C. Petrov
Jessica C. Petrov
PKPriyanka Kumar
Priyanka Kumar
ADAndrew J. Duffy
Andrew J. Duffy
TMThiruvengadam Muniraj
Thiruvengadam Muniraj

1 December 2015 in Journal of Critical Care
Verified
Journal Article
Closed access
TMThiruvengadam Muniraj
Thiruvengadam Muniraj
SDSaurabh Dang
Saurabh Dang
CPCapecomorin S. Pitchumoni
Capecomorin S. Pitchumoni

30 September 2020 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
TMThomas R. McCarty
Thomas R. McCarty
ABAhmad Najdat Bazarbashi
Ahmad Najdat Bazarbashi
BNBasile Njei
Basile Njei
MRMarvin Ryou
Marvin Ryou
HAHarry R. Aslanian
Harry R. Aslanian
TMThiruvengadam Muniraj
Thiruvengadam Muniraj
Percutaneous liver biopsy (PCLB) or transjugular liver biopsy (TJLB) have traditionally been performed to obtain a sample of hepatic tissue; however, endoscopic ultrasound-guided liver biopsy (EUSLB) has become an attractive alternative. The aim of this study was to compare the efficacy and safety of EUSLB, PCLB, and TJLB. Search strategies were developed in accordance with PRISMA and MOOSE guidelines. Major outcomes included the following: adequacy of biopsy specimens (i.e., complete portal triads [CPT], total specimen length [TSL] in mm, and length of longest piece [LLP]) in mm), and rate of adverse events. Only studies comparing all biopsy approaches (i.e., EUSLB, PCLB, and TJLB) were included. Five studies (EUSLB [n=301]; PCLB [n=176]; and TJLB [n=179]) were included. Biopsy cumulative adequacy rates for EUSLB, PCLB, and TJLB were 93.51%, 98.27%, and 97.61%, respectively. Based on the subgroup analysis limited to EUS biopsy needles in current clinical practice, there was no difference in biopsy adequacy or adverse events for EUSLB compared to PCLB and TJLB (all p>0.050). A comparison of EUSLB and PCLB revealed no difference between specimens regarding both CPT (p=0.079) and LLP (p=0.085); however, a longer TSL (p<0.001) was observed. Compared to TJLB, EUSLB showed no difference in LLP (p=0.351), fewer CPT (p=0.042), and longer TSL (p=0.005). EUSLB appears to be a safe, minimally invasive procedure that is comparable to PCLB and TJLB regarding biopsy specimens obtained and rate of adverse events associated with each method.

14 October 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
RLRobert Lam
Robert Lam
TMThiruvengadam Muniraj
Thiruvengadam Muniraj
Fully covered metal biliary stents: A review of the literature

23 March 2015 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
TMThiruvengadam Muniraj
Thiruvengadam Muniraj
ASAra Sahakian
Ara Sahakian
MCMaria M. Ciarleglio
Maria M. Ciarleglio
YDYanhong Deng
Yanhong Deng
HAHarry R. Aslanian
Harry R. Aslanian
Colonoscopic polypectomy has been shown to reduce the risk of colorectal cancer and the mortality. Postpolypectomy bleeding was reported to be lower with cold snare polypectomy (CSP) when compared with conventional polypectomy. CSP has traditionally been utilized only in smaller polyps below 1 cm. We retrospectively analyzed the CSP outcomes in patients with sessile polyps≥10 mm in size and observed that CSP was feasible in large sessile polyps with no adverse events and with an acceptable rate of residual polyp on follow-up colonoscopy. Further prospective study in larger patient groups is warranted to determine optimal CSP techniques and whether CSP for large polyps has favorable efficacy in regard to complete polypectomy, procedure time, and complication rates relative to polypectomy with cautery.

23 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
NMNitish Mittal
Nitish Mittal
VOVeeral M Oza
Veeral M Oza
TMThiruvengadam Muniraj
Thiruvengadam Muniraj
TKTruptesh Kothari
Truptesh Kothari
Acute pancreatitis is an inflammatory condition of the exocrine pancreas that is a common indication for hospital admission and has had an increasing incidence in the last few decades. The diagnosis of acute pancreatitis requires the satisfaction of two out of three criteria: (1) abdominal pain radiating to the back, (2) serum lipase or amylase levels three or more times the upper limit of the normal level, and (3) findings indicating pancreatitis obtained via a computed tomography (CT) scan or magnetic resonance imaging (MRI). The different etiologies include gallstones, autoimmune disorders, alcohol abuse, smoking, hypertriglyceridemia, obesity, drugs, and post-endoscope retrograde cholangiopancreatography (ERCP). The initial investigation includes serum amylase and lipase analysis, a lipid panel including triglycerides, analysis of immunoglobulins, a full blood count, electrolyte analysis, a hemoglobin A1c test, a complete metabolic panel, and transabdominal ultrasound. The initial therapy includes oxygen supplementation, the provision of intravenous fluids, pain control, and a nutrition regime. Early oral feeding is encouraged if tolerated; if not, liquid supplement provision or enteral tube feeding within 48 h of admission has shown better outcomes. Some complications of acute pancreatitis are necrosis, infection, insulin resistance leading to diabetes mellitus, and pancreatic exocrine insufficiency requiring enzyme supplementation. Patients need to attend regular follow-ups and abstain from alcohol and smoking (if warranted) to prevent the recurrence of acute pancreatitis. The mortality rate of acute pancreatitis has decreased in the past few decades because of better management skills, but the recent rise in acute pancreatitis episodes is concerning. Sustained endeavors through clinical trials are required to establish a broad variety of drugs that can be used for acute pancreatitis episodes.